Using Cheminformatics in Drug Discovery
- 1 January 2015
- book chapter
- Published by Springer Nature
- Vol. 232, 139-168
Abstract
This chapter illustrates how cheminformatics can be applied to designing novel compounds that are active at the primary target and have good predicted ADMET properties. Examples of various cheminformatics techniques are illustrated in the process of designing inhibitors that inhibit both cyclooxygenase isoforms but are more potent toward COX-2. The first step in the process is to create a knowledge database of cyclooxygenase inhibitors in the public domain. This data was analyzed to find activity cliffs – small structural changes that result in drastic changes in potency. Additional cyclooxygenase potency and selectivity trends were obtained using matched molecular pair analysis. QSAR models were then developed to predict cyclooxygenase potency and selectivity. Next, computational algorithms were used to generate novel scaffolds starting from known cyclooxygenase inhibitors. Nine virtual libraries containing 240 compounds each were constructed. Predictions from the cyclooxygenase QSAR models were used to eliminate molecules with undesirable potency or selectivity. Additionally, the compounds were screened in silico for undesirable ADMET properties, e.g., low solubility, permeability, metabolic stability, or high toxicity, using a liability scoring system known as ADMET Risk™. Eight synthetic candidates were identified from this process after incorporating knowledge gained from activity cliff analysis. Four of the compounds were synthesized and tested to measure their COX-1 and COX-2 IC50 values as well as several ADME properties. The best compound, SLP0020, had a COX-1 IC50 of 770 nM and COX-2 IC50 of 130 nM.Keywords
This publication has 20 references indexed in Scilit:
- A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityRheumatology International, 2011
- ChEMBL: a large-scale bioactivity database for drug discoveryNucleic Acids Research, 2011
- How not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR)SAR and QSAR in Environmental Research, 2009
- Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonThe Lancet, 2006
- On Outliers and Activity CliffsWhy QSAR Often DisappointsJournal of Chemical Information and Modeling, 2006
- Three-Dimensional Quantitative Structure−Activity Relationships of Cyclo-oxygenase-2 (COX-2) Inhibitors: A Comparative Molecular Field AnalysisJournal of Medicinal Chemistry, 2001
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001
- 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitorsBioorganic & Medicinal Chemistry Letters, 1998
- RECAPRetrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial ChemistryJournal of Chemical Information and Computer Sciences, 1998
- Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1European Journal of Pharmacology, 1995